









Mercado
/
Acciones
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

452.222USD

+10.522+2.38%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

59.60BCap. mercado

1368.04P/E TTM



Alnylam Pharmaceuticals Inc

452.222

+10.522+2.38%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Alnylam Pharmaceuticals Inc Compañía

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Información de Alnylam Pharmaceuticals Inc



Símbolo de cotizaciónALNY

Nombre de la empresaAlnylam Pharmaceuticals Inc

Fecha de salida a bolsaMay 28, 2004

Director ejecutivoDr. Yvonne L. Greenstreet, M.D.

Número de empleados2230

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 28

Dirección675 W Kendall St

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02142-1168

Teléfono16175518200

Sitio Webhttps://www.alnylam.com/

Símbolo de cotizaciónALNY

Fecha de salida a bolsaMay 28, 2004

Director ejecutivoDr. Yvonne L. Greenstreet, M.D.

Ejecutivos de Alnylam Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

Mr. Peter N. Kellogg

Independent Director

775.00

Ms. Colleen F. Reitan

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

Por negocioUSD

Nombre

Ganancia

Proporción

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

Otro

50.81M

6.57%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

454.57M

58.75%

Europe

157.01M

20.29%

Net revenues from collaborations

61.50M

7.95%

Rest of World

60.63M

7.84%

Royalty revenue

39.98M

5.17%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

Otro

50.81M

6.57%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

Otro

55.28%

Accionistas

Proporción

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

Otro

55.28%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

68.97%

Investment Advisor/Hedge Fund

21.97%

Hedge Fund

3.70%

Research Firm

1.84%

Sovereign Wealth Fund

1.63%

Bank and Trust

1.27%

Pension Fund

1.27%

Corporation

1.05%

Individual Investor

0.42%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

1364

130.85M

99.04%

-1.89M

2025Q2

1300

131.78M

100.54%

-3.28M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Capital World Investors

16.81M

12.82%

+55.38K

+0.33%

Jun 30, 2025

Fidelity Management & Research Company LLC

15.05M

11.48%

+427.38K

+2.92%

Jun 30, 2025

The Vanguard Group, Inc.

13.24M

10.1%

+238.24K

+1.83%

Jun 30, 2025

Capital Research Global Investors

7.19M

5.49%

+36.93K

+0.52%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.53M

4.98%

-199.00K

-2.96%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

4.28M

3.27%

-136.87K

-3.10%

Jun 30, 2025

JP Morgan Asset Management

1.79M

1.37%

-87.08K

-4.64%

Jun 30, 2025

Dodge & Cox

3.20M

2.44%

-154.67K

-4.61%

Jun 30, 2025

State Street Investment Management (US)

3.17M

2.42%

-193.48K

-5.75%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.05M

2.32%

-359.26K

-10.55%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Global X Genomics & Biotechnology ETF

6.7%

ProShares Ultra Nasdaq Biotechnology

6.12%

Invesco Nasdaq Biotechnology ETF

5.99%

iShares Biotechnology ETF

5.42%

Franklin Genomic Advancements ETF

5.21%

VanEck Biotech ETF

4.84%

First Trust NYSE Arca Biotechnology Index Fund

4.5%

American Century Focused Dynamic Growth ETF

4.11%

Pinnacle Focused Opportunities ETF

3.71%

Invesco NASDAQ Next Gen 100 ETF

3.42%

Global X Genomics & Biotechnology ETF

Proporción6.7%

ProShares Ultra Nasdaq Biotechnology

Proporción6.12%

Invesco Nasdaq Biotechnology ETF

Proporción5.99%

iShares Biotechnology ETF

Proporción5.42%

Franklin Genomic Advancements ETF

Proporción5.21%

VanEck Biotech ETF

Proporción4.84%

First Trust NYSE Arca Biotechnology Index Fund

Proporción4.5%

American Century Focused Dynamic Growth ETF

Proporción4.11%

Pinnacle Focused Opportunities ETF

Proporción3.71%

Invesco NASDAQ Next Gen 100 ETF

Proporción3.42%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

